Disodium Pentaborate Decahydrate up-regulates expressions of MAP kinase genes in human prostate cancer cells

Öz

Objectives: This study aims to investigate the expressions of MAP2K3, MAP3K7, and MAPK8 genes after disodium pentaborate decahydrate (DPD)treatment in DU-145 cells.

Materials and methods: Effect of DPD treatment on expressions of MAP2K3, MAP3K7, and MAPK8 genes were determined by qRT-PCR.

Results: We determined that disodium pentaborate decahydrate treatment increased the expressions of MAP2K3, MAP3K7, and MAPK8 genes in termsof mRNA levels.

Conclusion: The reason of increased apoptosis might be associated with high expression levels of MAP2K3, MAP3K7, and MAPK8 genes after DPDtreatment. Our novel findings suggest

Anahtar Kelimeler

• Disodyum pentaborat dekahidrat,gen ekspresyonu,prostat kanseri

Prostat kanseri hücrelerinde MAP kinaz gen ekspresyonlarını yukarı doğru regüle eden disodyum pentaborat dekahidrat

Öz

Amaç: Bu çalışmada DU-145 hücrelerinde disodyum pentaborat dekahidrat (DPD) uygulamasının ardından MAP2K3, MAP3K7 ve MAPK8 genlerinin ekspresyonları araştırıldı.Gereç ve yöntemler: Disodyum pentaborat dekahidrat uygulamasının MAP2K3, MAP3K7 ve MAPK8 genlerinin ekspresyonlarına olan etkisi qRT-PCR ile belirlendi.Bulgular: Disodyum pentaborat dekahidrat uygulamasının MAP2K3, MAP3K7 ve MAPK8 genlerinin mRNA seviyelerini artırdığı belirlendi.Sonuç: Apoptoz artışının, MAP2K3, MAP3K7 ve MAPK8 genlerinin DPD uygulaması sonrasında yükselen ekspresyon seviyelerine bağlı olarak gerçekleştiği düşünülmektedir. Güncel bulgularımız DPD’nin prostat kanseri tedavisinde mitojenik ve çevresel strese karşı apoptoza neden olan önemli bir etken olabileceğini öngörmektedir

Anahtar Kelimeler

• Disodyum pentaborat dekahidrat, gen ekspresyonu, prostat kanseri

Kaynakça

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220-41.
3. Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 2006;99:333-44.
4. Kohli M, Tindall DJ. New developments in the medical management of prostate cancer. Mayo Clin Proc 2010;85:77-86.
5. Basu S, Tindall DJ. Androgen action in prostate cancer. Horm Cancer 2010;1:223-8.
6. Rathkopf D, Scher HI. Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J 2013;19:43-9.
7. Rove KO, Crawford ED. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer. Curr Opin Urol 2013;23:208-13.
8. Barranco WT, Hudak PF, Eckhert CD. Evaluation of ecological and in vitro effects of boron on prostate cancer risk (United States). Cancer Causes Control 2007;18:71-7.

9. Cui Y, Winton MI, Zhang ZF, Rainey C, Marshall J, De Kernion JB, et al. Dietary boron intake and prostate cancer risk. Oncol Rep 2004;11:887-92.
10. Barranco WT, Eckhert CD. Boric acid inhibits
11. human prostate cancer cell proliferation. Cancer Lett 2004;216:21-9.
12. Barranco WT, Eckhert CD. Cellular changes in boric acid-treated DU-145 prostate cancer cells. Br J Cancer 2006;94:884-90.
13. McAuley EM, Bradke TA, Plopper GE. Phenylboronic acid is a more potent inhibitor than boric acid of key signaling networks involved in cancer cell migration. Cell Adh Migr 2011;5:382-6.
14. Jia M, Souchelnytskyi N, Hellman U, O’Hare M, Jat PS, Souchelnytskyi S. Proteome profiling of immortalization-to-senescence transition of human breast epithelial cells identified MAP2K3 as a senescence-promoting protein which is downregulated in human breast cancer. Proteomics Clin Appl 2010;4:816-28.
15. Wen HC, Avivar-Valderas A, Sosa MS, Girnius N, Farias EF, Davis RJ, et al. p38a Signaling Induces Anoikis and Lumen Formation During Mammary Morphogenesis. Sci Signal 2011;4:34.
16. Permpongkosol S, Wang JD, Takahara S, Matsumiya K, Nonomura N, Nishimura K, et al. Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. Int J Cancer 2002;98:167-72.
17. Kluth M, Hesse J, Heinl A, Krohn A, Steurer S, Sirma H, et al. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod Pathol 2013;26:975-83.
18. Liu W, Chang BL, Cramer S, Koty PP, Li T, Sun J, et al. Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers. Clin Cancer Res 2007;13:5028-33.
19. Guo J, Zhu T, Xiao ZX, Chen CY. Modulation of intracellular signaling pathways to induce apoptosis in prostate cancer cells. J Biol Chem 2007;282:24364-72.
20. Korkmaz M, Avci CB, Gunduz C, Aygunes D, Erbaykent-Tepedelen B. Disodium pentaborate decahydrate (DPD) induced apoptosis by decreasing hTERT enzyme activity and disrupting F-actin organization of prostate cancer cells. Tumor Biol 2014;35:1531-8.
21. Chiu SC, Wang MJ, Yang HH, Chen SP, Huang SY, Chen YL, et al. Activation of NAG-1 via JNK signaling revealed an isochaihulactone-triggered cell death in human LNCaP prostate cancer cells. BMC Cancer 2011;11:146.
22. Jiang C, Wang Z, Ganther H, Lü J. Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther 2002;1:1059-66.